RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Identification of a clinical candidate targeting HSP90
Fadden, P., Huang, K., Veal, J., Steed, P., Barabasz, A., Foley, B., Hu, M., Partridge, J., Rice, J., Scott, A., Dubois, L., Freed, T., Silinski, M., Barta, T., Hughes, P., Ommen, A., Ma, W., Smith, E., Spangenberg, A., ... Hall, S. (2010). Application of chemoproteomics to drug discovery: Identification of a clinical candidate targeting HSP90. Chemistry and Biology, 17(7), 686-694. https://doi.org/10.1016/j.chembiol.2010.04.015
A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chemical library prior to target selection. This chemoproteomics-based process enables a data-driven selection of both the biological target and chemical hit after the screen is complete. The methodology has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD). Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncology target Hsp90. The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clinical studies.
